Cancer vaccine target pinpointed - BBC News

Scientists may be one measure closer to producing a specific targeted vaccine for killing malignant neoplastic disease cells.

UK research workers have got pinpointed a protein on immune cells which they trust will assist them harness the body's defense mechanisms to assail a tumour.

A vaccine designed to "home in" on the protein would present a message to the immune system to assail the invading cancer, they said.

The research is published in the Diary of Clinical Investigation.

The protein is alone to a type of immune cell called a dendritic cell, which is responsible for triggering the body's defense mechanism system.

The consequences of this research are an of import measure towards apprehension how to make targeted malignant neoplastic disease vaccines in the future

Dr Lesley Walker, Cancer Research UK

Its occupation is to show pathogens or foreign molecules to other cells of the immune system, which in bend get rid of them.

The squad at Cancer Research UK's Greater London Research Institute said men of science have got been searching for proteins or "tags" on dendritic cells for over 30 years.

In theory a vaccine carrying a foreign molecule from a malignant neoplastic disease cell could be targeted to the dendritic cells, which would then motivate the immune system to assail the "invading" cancer. The same attack could be used for treating human immunodeficiency virus or malaria, the research workers said.

T cell army

Study leader Dr Caetano Reis vitamin E John Philip Sousa said the squad had establish a alone protein called DNGR-1, which could be used to present such as a vaccine to the door of the dendritic cell.

"Vaccines work by triggering an regular army of immune cells, called Deoxythymidine Monophosphate cells, to assail potentially unsafe foreign molecules, like those establish on pathogens.

"Dendritic cells are the messengers, telling the Deoxythymidine Monophosphate cells who to attack.

"Vaccines will transport a sample of the offending molecule and show it to DNGR-1 on the dendritic cells, which in bend will present the molecule to the regular armies of Deoxythymidine Monophosphate cells and instruct them to attack."

Cancer Research UK's manager of malignant neoplastic disease information, Dr Lesley Walker, said: "Developing treatments that accurately aim malignant neoplastic disease and have got few serious side-effects is one of Cancer Research UK's top goals.

"The consequences of this research are an of import measure towards apprehension how to make targeted malignant neoplastic disease vaccines in the future."

Mutant gene behind cancer identified

LONDON:
Scientists at University College London’s Prostate Gland Cancer Research Centre
have identified a mutant factor that assists distribute prostate gland malignant neoplastic disease through the
body. The research workers believe
that their discovery survey will pave the manner for drugs which mark the
mutation and halt the cancer
spreading. "We have got identified
mutations in a factor that assists to command cell movement. We believe that the
cancer cells have got hijacked this factor to assist them spread,” said Dr Magali
Williamson, who led the squad at the Prostate Gland Cancer Research Centre at
University College London. "We
found mutants in nearly half of the malignant neoplastic diseases restricted to the prostate, and
nearly all the 1s that have got spread, suggesting that the mutants might be
helping the malignant neoplastic disease cells spread," he
added. During the study, the
researchers examined 12 prostate gland malignant neoplastic disease patients whose disease had spread, and
found that 90 percentage of them had the mutant
gene. They also looked at 100
men whose malignant neoplastic disease had not spread, and observed that lone 45 percentage of them had
the mutant gene. They have got also
found that work force who were fleshy when diagnosed with prostate gland malignant neoplastic disease were
twice more than likely to decease from the
disease. Professor John
Masters, a specializer at the centre, said: "If we could switch over off this gene
with drugs we might forestall its spreading and salvage lives.”

Faulty gene link to breast cancer

Scientists say they have linked a faulty copy of a gene with the development of breast cancer.

Researchers in London and Italy studying biopsies found that Tip60 did not work as actively in breast cancer tissue as it did in normal tissue.

Low Tip60 activity was particularly associated with aggressive tumours.

The scientists said their findings, which are published in Nature, had implications for the treatment of women with the disease.

If low levels of Tip60 activity suggest a woman has a particularly aggressive form of the disease, she could be treated accordingly.

"More aggressive types of breast cancers tend to recur after treatment, spread to other parts of the body, and respond less well to chemotherapy," said Dr Tim Crook, the team leader at The Breakthrough Breast Cancer Research Centre.

"The identification of Tip60's role in breast cancer is a step forward towards predicting the aggressiveness of the disease and then individualising chemotherapy for women."

One faulty gene

Tip60 is a so-called tumour suppressor gene: it helps to hold the growth of cells in check.

Scientists found that reduced activity of the gene contributed to uncontrolled cell growth, which in turn allowed breast cancer to develop.

They also found that reduced levels of Tip60 were caused by only one faulty copy of the gene.

When we are born we inherit a copy of the gene from our mother and our father. Typically with tumour suppressor genes, both copies must be faulty for the function to be lost.

But the scientists said that the Tip60 gene stops working if only one copy is faulty.

Antonia Dean of Breast Cancer Care said scientists were still a long way from fully understanding the role genes play in the development of breast cancer, "and how this interacts with or is mediated by other factors".

"This is initial research. Further studies are needed to fully determine how these findings can be translated into practical benefits for people with breast cancer and the exact role Tip60 may have in the development of the disease."